THOROFARE, NJ / ACCESSWIRE / December 10, 2019 / Akers Biosciences, Inc. (NASDAQ:AKER), will be presenting at this year’s Investor Summit on December 17th in Philadelphia.
The Investor Summit will take place at Hotel Monaco, featuring 30 companies and over 200 institutional and retail investors.
About Akers Biosciences, Inc.
Akers Biosciences, Inc. (aka Akers Bio) was founded in 1989, with the objective of developing proprietary, in vitro diagnostic technologies that accelerate the rate at which clinicians, and in some cases consumers, can obtain health information. The tests and sample preparation devices that emerge from our rapid technology platforms are designed to provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time.
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
To register as a presenting company please email info@microcapconf.com.
To request complimentary investor registration: please visit our website at www.microcapconf.com.
News Compliments of ACCESSWIRE
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Ashley Allard at ashley@microcapconf.com
SOURCE: Akers Biosciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/569750/Akers-Biosciences-to-Present-at-the-Investor-Summit-on-December-17th-in-Philadelphia
NEWARK, DE / ACCESSWIRE / November 22, 2024 / Laurel Bridge Software, a leader in…
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or…
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New…
Diarrhea is one of the most common reasons for veterinary visits for dogs and the…
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers…
FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the…